Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis
Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Le Pen, Claude; Sinègre, Martine (2014), Biosimilar Granulocyte Colony-Stimulating Factor Uptakes in the EU-5 Markets: A Descriptive Analysis, Applied Health Economics and Health Policy, 12, 3, p. 315-326. 10.1007/s40258-014-0087-8
TypeArticle accepté pour publication ou publié
Journal nameApplied Health Economics and Health Policy
MetadataShow full item record
Institut Droit et Santé [IDS - U1145]
Institut Droit et Santé [IDS - U1145]
Le Pen, Claude
Abstract (EN)Background Biosimilars are copies of biological reference medicines. Unlike generics (copies of chemical molecules), biologics are complex, expensive and complicated to produce. The knowledge of the factors affecting the competition following patent expiry for biologics remains limited. Objectives The aims of this study were to analyse the EU-5 Granulocyte-Colon Stimulating Factor (G-CSF) markets and to determine the factors affecting the G-CSF biosimilar uptakes, particularly that of biosimilar prices relative to originators. Methods Data on medicine volumes, values, and ex-manufacturer prices for all G-CSF categories were provided by IMS Health. Volumes were calculated in defined daily doses (DDD) and prices in Euros per DDD. In the EU-5 countries, there is 5 years of experience with biosimilar G-CSFs (2007–2011). Results Two G-CSF market profiles exist: (1) countries with a high retail market distribution, which are the largest G-CSF markets with low global G-CSF biosimilar uptakes (5.4 % in France and 8.5 % in Germany in 2011); and (2) countries with a dominant hospital channel, which are the smallest markets with higher G-CSF biosimilar uptakes (12.4 % in Spain and 20.4 % in the UK). The more the decisions are decentralized, the more their uptakes are high. The price difference between G-CSF biosimilars and their reference plays a marginal role at a global level (price differences of +13.3 % in the UK and −20.4 % in France). Conclusion The competition with G-CSF biosimilars varies significantly between EU-5 countries, probably because of G-CSF distribution channel differences. Currently, this competition is not mainly based on prices, but on local political options to stimulate tendering between them and recently branded second- or third-generation products.
Subjects / KeywordsHealth Economics; Pharmacoeconomics and Health Outcomes; Public Health; Quality of Life Research
Showing items related by title and author.
A Long War Begins: Biosimilars Versus Patented Biologics – A Retrospective Analysis Of The Eu-5 And Japanese Erythropoetins Markets Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Le Pen, Claude; Sinègre, Martine (2014) Article accepté pour publication ou publié
To What Extent Can Biosimilars Compete with Brand Name Biologics? A EU-5 Granulocyte-Colony Stimulating Factors Markets Analysis Fusier, Isabelle; Cordonnier, Anne-Laure; Paubel, Pascal; Bocquet, François; Le Pen, Claude (2013) Article accepté pour publication ou publié
Biosimilar Versus Patented Erythropoietins: Learning from 5 Years of European and Japanese Experience Bocquet, François; Paubel, Pascal; Fusier, Isabelle; Cordonnier, Anne-Laure; Sinègre, Martine; Le Pen, Claude (2015) Article accepté pour publication ou publié
Temporary Authorization for Use: Does the French Patient Access Programme for Unlicensed Medicines Impact Market Access After Formal Licensing? Degrassat-Théas, Albane; Paubel, Pascal; Parent de Curzon, Olivier; Le Pen, Claude; Sinègre, Martine (2013) Article accepté pour publication ou publié
Temporary use authorizations : the economic and clinical future of drugs used in the french compassionate program Le Pen, Claude; Parent de Curzon, Olivier; Paubel, Pascal; Sinègre, Martine; Degrassat-Théas, Albane (2011) Article accepté pour publication ou publié